Brain Tumors | CHOP Research Institute

Taking CAR T-Cell Therapy to Solid Tumors and Beyond

Published on

Sep 19, 2022

Where Discovery Leads: CAR T-Cell Therapy Research

CHOP physician-scientists discuss their CAR T-cell therapy research for childhood cancers in Where Discovery Leads.

Leftover Surgical Specimen Collection Study (Brain Tumor Focus)

The Philadelphia Coalition for a Cure (PC4C) study is interested in collecting blood and saliva samples from you, as well as leftover tissue and cerebrospinal fluid from surgeries at CHOP.

ALRN-6924 in Pediatric Cancer

Evaluate the side effects and benefits of ALRN-6924 in patients with relapsed or treatment refractory solid tumor or brain tumor, and to determine the best dose of ALRN-6924 for children and adolescents.

Phase 1 Trial of CUDC-907

The overall goals of this study are to evaluate the side effects and benefits of CUDC-907 in patients with relapsed or treatment refractory solid tumor, brain tumor, or lymphoma, and to determine the best dose of CUDC-907 for children and adolescents.

Resnick and Storm Laboratory

Work in the Resnick and Storm Lab focuses on the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. The lab studies signaling cascades and alterations to elucidate the molecular and genetic underpinnings in order to develop targeted therapies.

Children's Brain Tumor Network Collection Protocol

The Children Brain Tumor Tissue Consortium (CBTTC) is a collaborative multi-institutional cooperative research program dedicated to the study of childhood brain tumors.

Cole Laboratory

Research in the Cole Lab focuses on identifying therapeutic vulnerabilities within molecularly defined subsets of pediatric central nervous system malignancies. The long-term goal of the lab is to identify effective therapies and improve the cure rate of children with malignant brain tumors.

Jessica B. Foster, MD

Dr. Foster’s current research focuses on immunotherapy for pediatric solid and brain tumors. Specifically she is investigating chimeric antigen receptor (CAR) T cell therapy for neuroblastoma, high-grade gliomas, medulloblastomas, diffuse intrinsic pontine gliomas, and other brain tumors. The goals of her research are to develop pre-clinical CAR T cells for translation into clinical trials to help these devastating tumors.

E-mail:

fosterjb [at] chop.edu

Adam C. Resnick, PhD

Dr. Resnick's research focuses on the cell signaling mechanisms of oncogenesis and tumor progression in brain tumors. He studies signaling cascades and alterations to elucidate the molecular and genetic underpinnings in order to develop targeted therapies. As co-director of the Center of Data-Driven Discovery in Biomedicine, he leads a multidisciplinary team building and supporting a scalable, patient-focused healthcare and educational discovery ecosystem.

E-mail:

resnick [at] chop.edu

Genetic Study Suggests Fine-Tuning Drugs for Pediatric Brain Tumors

Published on

Apr 23, 2013

in Cornerstone Blog

A new genetic study offers glimpses into how scientists might use gene-sequencing data to customize pediatric patients' cancer treatments. While investigating the biology of brain tumors in children, researchers at The Children's Hospital of Philadelphia found that crucial differences in how genes are mutated in a tumor may call for different treatments."